Analytical Quality by Design Approach for a Stability-Indicating Method to Determine Apixaban and Its Related Impurities
- 1 Downloads
Quality by Design (QbD) is a systematic approach that takes predefined objectives and emphasizes process understanding and control. Analytical QbD (AQbD) is widely used when it comes to the development and optimization of analytical methods. Since impurities and contaminants may be present in the pharmaceutical product, current regulatory guidelines recommend monitoring these substances. Thus, the aim of this work was to develop and validate a fast and sensitive stability indicating method by high-performance liquid chromatography (HPLC) for the simultaneous determination of apixaban and three synthesis impurities using AQbD approach. Experiments were designed and assessed on MODDE® 11 (Umetrics, Sweden) software and carried out in a Shimadzu® LC-20A Prominence HPLC–DAD at 220 nm. Design of experiments was applied to achieve the optimum conditions through response surface methodology with four quantitative critical method parameters (CMPs): column temperature, flow rate, mobile phase pH and organic percentage. Besides, the chromatographic column was the fifth CMP taken as a qualitative variable. The HPLC method was established using an Inertsil® CN-3 column at the temperature of 30 °C. The mobile phase consisted of methanol and water (50.2:49.8) at a flow rate of 1.015 mL/min with no pH adjustment. In order to confirm method selectivity excipients mixture was evaluated, as well as hydrolytic, photolytic, thermolytic, and oxidative conditions. The method was also validated for sensitivity (LOQ 0.5 μg/mL, LOD 0.01–0.05 μg/mL for impurities), linearity (concentration range 1–35 μg/mL for APX and 0.5–10 μg/mL for impurities, r > 0.999), precision (RSD ≤ 10%) and accuracy between levels (RSD < 3.0 for APX and < 4.0% for impurities). The application of AQbD led to a well-understood and validated analytical method that provided assured separation of APX and all significant impurities, turning it into a powerful decision-making tool for the analytical methodologies development.
KeywordsApixaban Quality-by-design AQbD Experimental design Drug impurities
Authors are thankful to CAPES and CNPq (Brazil) for financial support.
Compliance with Ethical Standards
Conflict of Interest
The authors declare the absence of conflicts of interest.
This article does not contain any studies with human participants performed by any of the authors.
- 5.International Conference on Harmonisation (2006) Impurities N Drug Subst Q3a(R2):15Google Scholar
- 6.Furlanetto S, Orlandini S, Pasquini B et al (2013) Quality by design approach in the development of a solvent-modified micellar electrokinetic chromatography method: finding the design space for the determination of amitriptyline and its impurities. Anal Chim Acta 802:113–124. https://doi.org/10.1016/j.aca.2013.10.005 CrossRefPubMedGoogle Scholar
- 12.Tantawy MA, El-Ragehy NA, Hassan NY, Abdelkawy M (2016) Stability-indicating spectrophotometric methods for determination of the anticoagulant drug apixaban in the presence of its hydrolytic degradation product. Spectrochim Acta Part A Mol Biomol Spectrosc. https://doi.org/10.1016/j.saa.2016.01.029 CrossRefGoogle Scholar
- 17.Maxwell BD, Tran SB, Chen SY et al (2011) The syntheses and in vitro biotransformation studies of [14C]apixaban, a highly potent, selective, efficacious and orally bioavailable inhibitor of blood coagulation Factor Xa. J Label Compd Radiopharm 54:418–425. https://doi.org/10.1002/jlcr.1890 CrossRefGoogle Scholar
- 18.Pinto DJP, Orwat MJ, Quan ML et al (2006) 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of bloo. Bioorganic Med Chem Lett 16:4141–4147. https://doi.org/10.1016/j.bmcl.2006.02.069 CrossRefGoogle Scholar
- 20.Christopher I, Ramsey P, Chant GR, et al (2015) (12) United States Patent (10) Patent NoGoogle Scholar
- 21.Xu Q, Shuang H, Weisi L et al (2015) Process for preparation od anti-thrombotic agent apixaban, China Patent CN 104892601 AGoogle Scholar
- 23.International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2009) ICH harmonised tripartite guideline, pharmaceutical development Q8(R2)Google Scholar
- 30.ICH (2005) Validation of a analytical Procedures : text and methodology Q2(R1). Guidance 1994:17. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf. Accessed 1 July 2017
- 33.International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2005) ICH harmonised tripartite guideline. Quality risk management Q9Google Scholar
- 35.Montgomery DC (2012) Design and analysis of experiments Livro montgomerry, 8th ednGoogle Scholar
- 36.Miller JN, Miller JC (2005) Statistics and chemometrics for analytical chemistry, 4th edn. Prentice HallGoogle Scholar
- 39.Zhang X, Hu C (2017) Application of quality by design concept to develop a dual gradient elution stability-indicating method for cloxacillin forced degradation studies using combined mixture-process variable models. J Chromatogr A 1514:44–53. https://doi.org/10.1016/j.chroma.2017.07.062 CrossRefPubMedGoogle Scholar
- 40.Landge SB, Jadhav SA, Dahale SB et al (2015) Development and validation of stability indicating RP-HPLC method on core shell column for determination of degradation and process related impurities of apixaban—an anticoagulant drug. Am J Anal Chem 6:539–550. https://doi.org/10.4236/ajac.2015.66052 CrossRefGoogle Scholar